Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...

SmartScripts has faced a welter of lawsuits and been fined for its sale of a counterfeit version of popular weight-loss drug Ozempic.

Novo Nordisk A/S ( NVO) trimmed its forecast for a fourth time this year on Wednesday, citing lower-than-expected sales of ...

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.

This article was reviewed by Lynn Marie Morski, MD, JD. How Long Does Ozempic® Stay in Your System? Key takeaways: Ozempic® ...

Scientists are investigating whether popular weight-loss drugs like Ozempic could influence fertility or interfere with birth ...

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.